In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Remains Primary Outlet For Innovative Brands As Attention Shifts To China – IMS

This article was originally published in PharmAsia News

Executive Summary

IMS sees more opportunity for new brands in Japan even as China is expected to become the second-largest pharma market.

You may also be interested in...

Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence

Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.

Are Novartis’ Advertising Charges In Japan The Tip Of The Iceberg?

Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.

HIV Treatment Options For Patients Improve In Japan

Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts